QIAGEN Reports Q1 Profit Drop, Restructuring Charges, and 5% Share Reduction
QGEN is trading near its 52-week low of $33.17 (0.9% above the low).
Summary
QIAGEN N.V. reported a 25% drop in Q1 net income and a 28% decline in cash from operations, alongside $32.2 million in restructuring charges, while completing a $496.7 million synthetic share repurchase.
Key Events · Earnings and Guidance · QGEN
-
Q1 Profitability and EPS Decline
Net income decreased by 25% to $68.0 million, and diluted earnings per common share fell by 19.5% to $0.33 in Q1 2026 compared to the prior year. Operating income also dropped by 26.8% to $84.4 million, with the operating income margin compressing to 17.1% from 23.9%.
-
Significant Restructuring and Impairment Charges
The company recorded $32.2 million in restructuring, acquisition, integration, and other net charges in Q1 2026. This includes a $15.2 million non-cash impairment from the abandonment of software assets under construction and $17.2 million in charges related to the 2025 restructuring program.
-
Cash Flow from Operations Decreases
Net cash provided by operating activities declined by 28% to $100.6 million in Q1 2026, down from $139.7 million in the year-ago period, primarily due to increased working capital requirements and payments for efficiency measures.
-
Completed $496.7M Synthetic Share Repurchase
In January 2026, QIAGEN completed a synthetic share repurchase, returning $496.7 million to shareholders and reducing the total number of outstanding shares by 5.0%. This follows a similar $280.1 million repurchase in January 2025.
Analysis · QGEN · Life Sciences
QIAGEN N.V. reported a significant decline in Q1 2026 profitability and cash flow from operations, with net income falling 25% and diluted EPS dropping nearly 20% year-over-year, despite a modest 2% increase in net sales. Operating income and gross margins also compressed, reflecting unfavorable impacts from tariffs, currency movements, and increased operating costs. The company incurred substantial restructuring charges of $32.2 million, including a $15.2 million impairment for abandoned software assets. This weak operational performance comes as the stock is trading near its 52-week low, amplifying investor concerns. The filing also details the completion of a previously announced synthetic share repurchase in January 2026, which returned $496.7 million to shareholders and reduced outstanding shares by 5.0%. While this is a significant capital deployment, it does not offset the underlying operational challenges highlighted in the quarter's results.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QGEN was trading at $33.46 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.9B. The 52-week trading range was $33.17 to $57.82. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.